QurieGen, a Nijmegen, the Netherlands-based cellular technology company, raised €2.2M in funding.
Backers included Tensor Ventures, Lighthouse Ventures, BSV Ventures, Moondust Ventures, and 22 Hor Invest, as well as Tim Draper of Draper Associates.
The company intends to use the funds to expand operations and its R&D efforts.
Led by Kinga Matula, CEO, QurieGen develops QuRIE-seq, a platform providing patented single-cell technology that enhances the drug discovery and development process. It enables the decoding of cellular responses by simultaneously quantifying mRNA molecules, as well as hundreds of membrane proteins, intracellular proteins, and phosphoproteins.
The company currently operates at the interface between the Netherlands and Poland, leveraging the scientific base in the Netherlands and the Polish technology ecosystem.
FinSMEs
08/04/2025